Terumo Cardiovascular Systems

e-mail usprint

Surface Coating

A Terumo survey of 300 U.S. chief perfusionists found that 74% used biocompatible coatings. Xcoating™ frequently referred to in scientific literature by its chemical name, PMEA, is Terumo's amphiphilic, biopassive coating.

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

CASE STUDY: Bloodless Cardiac Surgery is a Team Sport
Ninety percent of patients weighing over 25 kilos have surgery without receiving blood at The Heart Center at Nationwide Children's Hospital in Columbus, Ohio. Read about its blood management program.

STUDY: Pediatric Hospital Uses New Technology to Remove Gaseous Microemboli and Reduce Blood Usage
Nationwide Children's Hospital evaluated the CAPIOX FX Oxygenator with an integrated arterial filter and found it significantly reduced prime volume and GME.

CD-ROM: The Inflammatory Response to CPB - Continued Clinical Challenges and Technological Opportunities
Terence Gourlay, PhD, shares blood management studies from the University of Strathclyde in Scotland during the Optimizing Cardiac Surgery Symposia in Newport Beach, California in February 2010.

CD-ROM: Controlling SIRS: Can new technology impact outcomes?
Uwe Schonrock, CCP, discusses the use and results of a minimized circuit at Braunschweig Klinikum in Germany during his Optimizing Cardiac Surgery Symposia presentation in Newport Beach, California in February 2010.

CD-ROM: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass
Serdar Gunaydin, MD, PhD, presents clinically significant results using Xcoating and leukocyte filtration for high-risk patients at the May 2006 Optimizing Cardiac Surgery Symposium.

CD-ROM: Circuit Evolution and Patient Benefits
Ben Komorowski, CCP, shares the eight year evolution of the changes in his perfusion circuit at the Orlando 2006 Optimizing Cardiac Surgery Symposium.

CD-ROM: From Science to Clinical Practice: A Synergistic Approach to Reducing Blood Loss and the Inflammatory Response
David Fallen, CCP, discuss non-pharmacologic approaches to reducing bleeding and SIRS at the Optimizing Cardiac Surgery Symposium in May 2006.

CD-ROM: Benefits, Features and Results of Reduced Prime Circuits
Order a complimentary CDROM of the New Orleans 2005 Optimizing Cardiac Surgery Symposium (April 2005) to watch David Fallen, CCP's presentation on the use of reduced prime circuits.

ABSTRACT: Clinical Evaluation of Poly (2-methoxyethylacrylate) in Primary Coronary Artery Bypass Grafting. JECT 2005;37:23-31. Vang SN, et al.
The study demonstrates that the use of Xcoating™ compared to no coating results in lower WBC counts, less blood transfusions, and a cost savings of $83.41 per patient.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: A New Poly-2-Methoxyethylacrylate-Coated CPB Circuit Possesses Superior Platelet Preservation and Inflammatory Suppression Efficacy. Annals of Thoracic Surgery. 2004; 77:1678-1683 Ikuta T, et al.
This study compares the biocompatibility of PMEA-coated circuits to heparin-coated and non-coated circuits, focusing on platelet preservation and systemic inflammatory response.

ABSTRACT: Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.

ABSTRACT: Evaluation of a New Condensed Extracorporeal Circuit for Cardiac Surgery: A Prospective Randomized Clinical Pilot Study. Perfusion 2005; vol. 20, 91-99. Fransen, et al.
The authors noted an improvement in biocompatibility in a reduced prime circuit with Xcoating over a traditional circuit with heparin-coating.

ABSTRACT: Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including Xcoating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.

ABSTRACT: The CAPIOX RX05 Oxygenator: Pediatric Clinical Observations. Perfusion. 2003;18, 321-323, Tinius, et al.
The authors provide clinical observations on the use of the CAPIOX® BABY RX™ Oxygenator and reducing prime volume in neonate circuits.

ABSTRACT: Effects of New Polymer-Coated Extracorporeal Circuits on Biocompatibility During Cardiopulmonary Bypass. Artificial Organs, Volume 24, No 7, 2000. Saito, et al.
This study compares Xcoating™ to heparin coating in reducing the release of bradykinin and leukocyte activation during CPB.

ABSTRACT: Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.

ABSTRACT: Xcoating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of Xcoating.